use of tumor markers in testicular, prostate, colorectal, breast, and ...

72 Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
lymph node-negative breast cancer patients identified by urokinase-type
plasminogen activator and plasminogen activator
inhibitor type 1. J Natl Cancer Inst 2001;93:913–920.
363. Duffy MJ. Urokinase plasminogen activator and its inhibitor,
PAI-1, as prognostic markers in breast cancer: from pilot to level
1 evidence studies. Clin Chem 2002;48:1194–1197.
364. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion
factors urokinase-type plasminogen activator and plasminogen
activator inhibitor type 1 for individualized therapy decisions in
primary breast cancer is greatest when used in combination.
J Clin Oncol 2002;20:1000–1007.
365. Harbeck N, Kates RE, Look MP, Meijer-van Gelder ME, Klijn
JG, Kruger A, et al. Enhanced benefit from adjuvant
chemotherapy in breast cancer patients classified high-risk
according to urokinase-type plasminogen activator (uPA) and
plasminogen activator inhibitor type 1 (n = 3424). Cancer Res
2002;62:4617–4622.
366. Benraad TJ, Geurts-Moespot J, Grondahl-Hansen J, Schmitt M,
Heuvel JJ, de Witte JH, et al. Immunoassays (ELISA) of urokinase-type
plasminogen activator (uPA): report of an EORTC/
BIOMED-1 workshop. Eur J Cancer 1996;32A:1371–1381.
367. Sweep CG, Geurts-Moespot J, Grebenschikov N, de Witte JH,
Heuvel JJ, Schmitt M, et al. External quality assessment of trans-
European multicentre antigen determinations (enzyme-linked
immunosorbent assay) of urokinase-type plasminogen activator
(uPA) and its type 1 inhibitor (PAI-1) in human breast cancer
tissue extracts. Br J Cancer 1998;78:1434–1441.
368. Janicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl
A, Graeff H. Both the cytosols and detergent extracts of breast
cancer tissues are suited to evaluate the prognostic impact of
the urokinase-type plasminogen activator and its inhibitor,
plasminogen activator inhibitor type 1. Cancer Res 1994;
54:2527–2530.
369. Abraha RS, Thomssen C, Harbeck N, Mueller V, Baack K,
Schmitt M, et al. Micromethod for determination of uPA and
PAI-1 from preoperative core-needle biopsies in breast cancer.
Breast Cancer Res Treat 2003;82:S144.
370. Schmitt M, Lienert S, Prechtel D, Sedlaczek E, Welk ARU, et
al., et al. The urokinase protease system as a target for breast
cancer prognosis and therapy: technical considerations.
Procedure for the quantitative determination of urokinase (uPA)
and its inhibitor PAI-1 in human breast cancer tissue extracts by
ELISA, Vol.: Breast Cancer Protocols, 2005.
371. Molina R, Barak V, van DA, Duffy MJ, Einarsson R, Gion M,
et al. Tumor markers in breast cancer - European Group on Tumor
Markers recommendations. Tumour Biol 2005;26:281–293.
372. Pestalozzi BC, Luporsi-Gely E, Jost LM, Bergh J. ESMO
Minimum Clinical Recommendations for diagnosis, adjuvant
treatment and follow-up of primary breast cancer. Ann Oncol
2005;16 Suppl 1:i7–i9.
373. Kataja VV, Colleoni M, Bergh J. ESMO Minimum Clinical
Recommendations for diagnosis, treatment and follow-up of
locally recurrent or metastatic breast cancer (MBC). Ann Oncol
2005;16 Suppl 1:i10–i12.
374. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann
B, Senn HJ. Progress and promise: highlights of the international
expert consensus on the primary therapy of early breast
cancer 2007. Ann Oncol 2007;18:1133–1144.
375. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S,
et al. American Society of Clinical Oncology 2007 Update of
Recommendations for the Use of Tumor Markers in Breast
Cancer. J Clin Oncol 2007:In press. [e-pub ahead of print].
376. Jager W. The early detection of disseminated (metastasized)
breast cancer by serial tumour marker measurements. Eur J
Cancer Prev 1993;2 Suppl 3:133–139.
377. Nicolini A, Anselmi L, Michelassi C, Carpi A. Prolonged survival
by ‘early’ salvage treatment of breast cancer patients: a
retrospective 6-year study. Br J Cancer 1997;76:1106–1111.
378. Kovner F, Merimsky O, Hareuveni M, Wigler N, Chaitchik S.
Treatment of disease-negative but mucin-like carcinoma-associated
antigen-positive breast cancer patients with tamoxifen: preliminary
results of a prospective controlled randomized trial.
Cancer Chemother Pharmacol 1994;35:80–83.
379. Hayes DF, Kiang DT, Korzum AH, Tondini C, Wood WC, Kufe
DW. CA15-3 and CEA spikes during chemotherapy for metastatic
breast cancer. Proc Am Soc Clin Oncol 1998;7:38.
380. Yasasever V, Dincer M, Camlica H, Karaloglu D, Dalay N.
Utility of CA 15-3 and CEA in monitoring breast cancer patients
with bone metastases: special emphasis on “spiking” phenomena.
Clin Biochem 1997;30:53–56.
381. Duffy MJ. Serum tumor markers in breast cancer: are they of
clinical value? Clin Chem 2006;52:345–351.
382. Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, et al.
Recommendations for follow-up care of individuals with an inherited
predisposition to cancer. II. BRCA1 and BRCA2. Cancer
Genetics Studies Consortium. JAMA 1997;277:997–1003.
383. Nelson HD, Huffman LH, Fu R, Harris EL. Genetic risk assessment
and BRCA mutation testing for breast and ovarian cancer
susceptibility: systematic evidence review for the U.S.
Preventive Services Task Force. Ann Intern Med 2005;143:
362–379.
384. US Preventive Services Task Force. Genetic risk assessment and
BRCA mutation testing for breast and ovarian cancer susceptibility:
Recommendation statement. Ann Intern Med 2005;
143:355–361.
385. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the
clinic: when will molecular signatures become relevant to patient
care? Nat Rev Cancer 2007;7:545–553.
386. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB,
et al. Concordance among gene-expression-based predictors for
breast cancer. N Engl J Med 2006;355:560–569.
387. van’t Veer LJ, Dai H, van dV, M.J., He YD, Hart AA, Mao M,
et al. Gene expression profiling predicts clinical outcome of
breast cancer. Nature 2002;415:530–536.
388. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil
DW, et al. A gene-expression signature as a predictor of survival
in breast cancer. N Engl J Med 2002;347:1999–2009.
389. Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM,
et al. Validation and clinical utility of a 70-gene prognostic signature
for women with node-negative breast cancer. J Natl
Cancer Inst 2006;98:1183–1192.
390. Cardoso F, Van’t Veer L, Rutgers E, Loi S, Mook S, Piccart-
Gebhart MJ. Clinical application of the 70-gene profile: the
MINDACT trial. J Clin Oncol 2008;26:729–735.
391. Paik S. Development and clinical utility of a 21-gene recurrence
score prognostic assay in patients with early breast cancer
treated with tamoxifen. Oncologist 2007;12:631–635.
392. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene
assay to predict recurrence of tamoxifen-treated node-negative
breast cancer. N Engl J Med 2005;347:2817–2826.
393. Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M,
et al. A population-based study of tumor gene expression and
risk of breast cancer death among lymph node-negative patients.
Breast Cancer Res 2006;8:R25.